KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Change in Accured Expenses: 2009-2025

Historic Change in Accured Expenses for Arbutus Biopharma (ABUS) over the last 16 years, with Sep 2025 value amounting to $145,000.

  • Arbutus Biopharma's Change in Accured Expenses rose 104.07% to $145,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.9 million, marking a year-over-year decrease of 27.81%. This contributed to the annual value of -$2.7 million for FY2024, which is 52.99% up from last year.
  • According to the latest figures from Q3 2025, Arbutus Biopharma's Change in Accured Expenses is $145,000, which was up 101.91% from -$7.6 million recorded in Q2 2025.
  • In the past 5 years, Arbutus Biopharma's Change in Accured Expenses registered a high of $4.5 million during Q1 2025, and its lowest value of -$7.6 million during Q2 2025.
  • Its 3-year average for Change in Accured Expenses is -$1.0 million, with a median of $20,000 in 2024.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first skyrocketed by 590.69% in 2023, then plummeted by 456.04% in 2024.
  • Arbutus Biopharma's Change in Accured Expenses (Quarterly) stood at $1.3 million in 2021, then skyrocketed by 183.56% to $3.8 million in 2022, then slumped by 87.63% to $465,000 in 2023, then plummeted by 95.70% to $20,000 in 2024, then skyrocketed by 104.07% to $145,000 in 2025.
  • Its last three reported values are $145,000 in Q3 2025, -$7.6 million for Q2 2025, and $4.5 million during Q1 2025.